Christine Hunter
#82,438
Most Influential Person Now
American clinical psychologist and military officer
Christine Hunter's AcademicInfluence.com Rankings
Christine Hunterpsychology Degrees
Psychology
#4030
World Rank
#4507
Historical Rank
#1450
USA Rank
Clinical Psychology
#440
World Rank
#447
Historical Rank
#150
USA Rank
Download Badge
Psychology
Christine Hunter's Degrees
- Bachelors Psychology University of California, Berkeley
Similar Degrees You Can Earn
Why Is Christine Hunter Influential?
(Suggest an Edit or Addition)According to Wikipedia, Christine M. Hunter is an American clinical psychologist and a uniformed service officer. She is the acting National Institutes of Health associate director for behavioral and social sciences research and acting director of the NIH Office of Behavioral and Social Sciences Research. Hunter was an active duty officer in the U.S. Air Force from 1996 to 2006. She is a captain in the U.S. Public Health Service Commissioned Corps.
Christine Hunter's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The Parkinson Progression Marker Initiative (PPMI) (2011) (1159)
- A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. (2002) (547)
- A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. (2014) (294)
- The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
- A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease (2004) (231)
- Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. (2007) (218)
- A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease (2007) (204)
- Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders (2007) (171)
- Olanzapine treatment for dopaminergic‐induced hallucinations (2002) (163)
- Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. (2016) (152)
- National randomized controlled trial of virtual house calls for Parkinson disease (2017) (140)
- Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson’s disease (2002) (132)
- Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial (2000) (125)
- Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families (2007) (90)
- A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. (2002) (88)
- Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia (2008) (86)
- A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. (2007) (85)
- Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation (2005) (84)
- Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia (2006) (83)
- Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease (2012) (83)
- Distinguishing psychogenic and essential tremor (2007) (82)
- Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
- Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. (2008) (67)
- Effects of anti-VEGF antibody on blood–brain barrier disruption in focal cerebral ischemia (2007) (61)
- Continuous in-home monitoring of essential tremor. (2014) (61)
- A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease (2008) (60)
- Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. (2016) (54)
- Analysis of CYP2D6 genotype and response to tetrabenazine (2013) (51)
- Genetic analysis of LRRK2 mutations in patients with Parkinson disease (2006) (51)
- Short‐term effects of tetrabenazine on chorea associated with Huntington's disease (2007) (51)
- Is History of Depression a Contraindication to Treatment With Tetrabenazine? (2006) (50)
- Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits (2015) (48)
- Onabotulinum toxin-A injections for sleep bruxism (2018) (47)
- National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. (2016) (47)
- Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. (2021) (47)
- Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. (2006) (46)
- Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease (2009) (43)
- Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population (2007) (39)
- Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. (1999) (36)
- Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea (2017) (33)
- Effects of VEGF and nitric oxide synthase inhibition on blood–brain barrier disruption in the ischemic and non-ischemic cerebral cortex (2005) (33)
- A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease (1999) (32)
- Effects of blockade of ionotropic glutamate receptors on blood–brain barrier disruption in focal cerebral ischemia (2010) (30)
- A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. (2007) (29)
- Tetrabenazine in the treatment of Tourette syndrome (2007) (28)
- Flumazenil, a GABA antagonist, may improve features of Parkinson's disease (2003) (28)
- Effects of Erythropoietin on Blood-Brain Barrier Disruption in Focal Cerebral Ischemia (2008) (28)
- The Effects of Isoflurane Pretreatment on Cerebral Blood Flow, Capillary Permeability, and Oxygen Consumption in Focal Cerebral Ischemia in Rats (2010) (25)
- The Effects of Dexmedetomidine on Regional Cerebral Blood Flow and Oxygen Consumption During Severe Hemorrhagic Hypotension in Rats (2011) (24)
- Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington’s and Other Diseases (2013) (23)
- Age-dependent changes in brain glycine concentration and strychnine-induced seizures in the rat (1989) (21)
- Effects of Exogenous Excitatory Amino Acid Neurotransmitters on Blood–Brain Barrier Disruption in Focal Cerebral Ischemia (2009) (20)
- Apomorphine injections: predictors of initial common adverse events and long term tolerability. (2012) (19)
- Effects of GABAA receptor blockade on regional cerebral blood flow and blood–brain barrier disruption in focal cerebral ischemia (2011) (17)
- Effects of Fentanyl Pretreatment on Regional Cerebral Blood Flow in Focal Cerebral Ischemia in Rats (2010) (17)
- Effects of 17beta-estradiol on blood-brain barrier disruption during focal cerebral ischemia in younger and older rats. (2006) (17)
- Effects of VEGF on the Blood-Brain Barrier Disruption Caused by Hyperosmolarity (2008) (16)
- Effect of Tetrabenazine on Motor Function in Patients with Huntington Disease (2012) (15)
- Effects of deferoxamine on blood–brain barrier disruption and VEGF in focal cerebral ischemia (2008) (14)
- Effects of Cannabinoid Receptor Agonist WIN 55,212-2 on Blood-Brain Barrier Disruption in Focal Cerebral Ischemia in Rats (2012) (13)
- Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
- Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. (2011) (9)
- Effects of 17beta-estradiol on blood-brain barrier disruption in focal ischemia during GABA(A) receptor inhibition. (2005) (9)
- Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. (2021) (7)
- Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis. (2019) (5)
- Effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor blockade on increased cerebral O2 consumption in Eker rats (2009) (3)
- Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort (2022) (2)
- A Call to Action: The Role of Healthcare Providers in Reducing the Burden Associated with Neurogenic Orthostatic Hypotension (2020) (2)
- Onabotulinum Toxin-A Injections for Nocturnal Bruxism: A Parallel, Double Blind, Placebo Controlled Polysomnographic Study (P05.006) (2012) (2)
- The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study (2022) (2)
- Effects of blockade of NMDA receptors on cerebral oxygen consumption during hyperosmolar BBB disruption in rats (2013) (1)
- Effects of Deferoxamine on Blood-Brain Barrier Disruption and VEGF in Focal Cerebral Ischemia (2006) (1)
- Effects of Anti-VEGF Antibody on Blood-Brain Barrier Disruption in Focal Cerebral Ischemia (2006) (1)
- Fox Trial Finder: An Innovative Web-Based Trial Matching Tool To Facilitate Clinical Trial Recruitment (P02.241) (2012) (1)
- Baylor Functional Assessment Scale (2021) (0)
- Effects of a PDGFR-a Antagonist Imatinib on Blood-Brain Barrier Disruption in Focal Cerebral Ischemia in Younger and Older Rats (2012) (0)
- Tetrabenazine for Moderate vs. Severe/Disabling Chorea Associated with Huntington's Disease (HD) (P06.032) (2012) (0)
- Long-Term Safety and Efficacy of Tetrabenazine in the Treatment of Chorea Associated with Huntington's Disease (P06.034) (2012) (0)
- Abstracts from ASENT 2004 Annual Meeting March 11–13, 2004 (2004) (0)
- Parkinson's Progression Markers Initiative brain autopsy program. (2022) (0)
- Contents Vol. 89, 2012 (2012) (0)
- Diagnostic Reliability of DaTscan in Movement Disorders (P03.125) (2012) (0)
- Continuous Home Monitoring of Essential Tremor Using Motion Sensors (P05.035) (2013) (0)
- Proteome Signature of Superior Temporal Gyrus and Effects of Anti-psychotic Drug Treatment in Non-Human Primates (2010) (0)
- Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson disease heterogeneity (2020) (0)
- Concomitant Use of Antidepressants and Neuroleptics with Tetrabenazine during Treatment of Huntington's Disease (HD) (P06.039) (2012) (0)
- Metoclopramide, an Increasingly Recognized Cause (2008) (0)
- A validation of a self-administered screening test for Parkinson's disease (2020) (0)
- Abstracts from ASENT 2004 Annual Meeting March 11–13, 2004 (2004) (0)
This paper list is powered by the following services:
Other Resources About Christine Hunter
What Schools Are Affiliated With Christine Hunter?
Christine Hunter is affiliated with the following schools:
